Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Article CommentaryCommentary

Treating Cervical Dysplasia: Why Does It Matter?

Niharika Khanna
The Journal of the American Board of Family Medicine March 2010, 23 (2) 151-153; DOI: https://doi.org/10.3122/jabfm.2010.02.100005
Niharika Khanna
MBBS, MD, DGO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

The cone biopsy described in the case series discussed by Mulhem et al1 touches on several key issues in cervical cancer prevention and within the scope of practice of family physicians. In the current medical environment health care reform to bolster primary care to reduce health care costs are being proposed; such internal discussions within the family medicine community are timely and germane to reform.2–5 The role of family medicine specialists in implementing and translating technological advances in science into clinical practice is undervalued and unappreciated within the medical system hierarchy.6 There is a need for family physicians to lead the way in adopting and implementing such new technologies into clinical practice and generating implementation, service, and patient-related outcomes data, which evidence rigorous evaluation within real-world settings.

The Big Picture

In the United States and other developed countries, cervical cancer prevention with organized screening programs is actively taking new shape. Since the 1950s and the widespread use of Papanicolaou smear screening there has been a decline in the number of cervical cancers in the United States, with 11,070 invasive cervical cancers detected in 2008 and 4,070 deaths.7 Concurrent to the decrease in cervical cancer is an observed increase in the detection of cervical precancer or cervical intraepithelial neoplasia (CIN). Screening practices using cytology and human papillomavirus (HPV) typing has lead to the detection of an estimated 20 million women in the United States who are already infected with HPV and 1.875 million women infected with CIN per year. In addition, Papanicolaou smear detects 2 million women with atypical squamous cells of unknown significance.8 This process has lead to large numbers of women who are seen within family practices nationwide who need intervention after being diagnosed with a non–life-threatening precancer.

HPV Vaccine

The prophylactic L1 subunit HPV vaccine is one of the technological advance of this century. However, administration of the vaccine and its implementation into clinical practice has been poorly accepted, particularly among target populations including minority women with a high prevalence of HPV infection. The true potential of this vaccine has not been realized because of imperfect penetration within the community and subpar vaccination of the US population.9 Assuming that translational science in clinical implementation accrues in HPV vaccine delivery, leading to significant increases in populations that have been vaccinated against HPV, there still are expected to be millions of US women who are already infected with the HPV and thus at risk for CIN. In addition, the vaccine contains 2 of the many HPV subtypes that cause dysplasia and cancer, leaving women unprotected against other HPV strains that account for 30% of cervical disease. Thus, in the foreseeable future there will be a need to refine the management of CIN within primary care and will require judicious consultation with our gynecological colleagues.

Management of CIN

Management of CIN uses a framework that is set by the American Society for Colposcopy and Cervical Pathology, a multidisciplinary group that has provided guidance applicable in most clinical settings, including primary care/family medicine.10 Guidance from this group has become more conservative as the science of HPV infection and HPV-linked CIN advances. Recent iterations of the American Society for Colposcopy and Cervical Pathology's guidance have used age as the primary categorization of risk. New guidelines are linked to age, which suggests a need for greater restraint in screening girls younger than 20 because of the risks of overtreatment with excisional cervical biopsies. Although alternatives to excisional biopsy or cervical ablation are in early-phase therapeutic clinical trials (eg, terameprocol used topically for CIN), they are not standard of care.11 Further, utilization of excisional biopsy is standard of care in cases of CIN II and/or III in adult women unless there are clear parameters that contradict the use of loop electrosurgical excision procedure (LEEP).

Family Medicine's Role in the Management of CIN

Cervical excisional biopsy, including LEEP training within family medicine residencies, is not consistent. Although some residencies provide women's health training, including colposcopy and LEEP, many residencies do not provide this training. However, the contradiction in needs and training becomes more evident when considering that a large proportion of all Papanicolaou smears performed in the United States are generated in family practice offices and results of the tests are processed there as well. Follow-up colposcopy and biopsy is very often performed within family practice offices. Rigorous evaluation of colposcopy in trials comparing the performance of colposcopy in detecting cervical disease and comparing this to the level of training of the operator (e, gynecologic oncologist, gynecologist, general practitioner, nurse practitioner) suggests that the level of operator training does not influence the results of the colposcopy. Rather, the number of biopsies obtained by colposcopy is directly related to the disease yield for cervical dysplasia.12,13 Thus, evidence suggests that obtaining 2 or more biopsies during colposcopy has excellent yield. Intuitively, adding an endocervical curettage should increase the yield for endocervical disease in women older than 30.14

If we extrapolate from the results of real-life implementation outcomes observations in colposcopy, it would suggest that excisional biopsy, including LEEP, in the hands of trained practitioners from any discipline should have similar yield. However, there are inevitably low numbers of CIN II and III diagnosed in family medicine and thus less opportunity for adequate training in cone biopsy using the LEEP. Using the assumption that lower numbers of procedures within a practice are associated with higher number of adverse events, it would be reasonable to consider the use of an assistive device such as the Fischer cone biopsy. Use of the Fischer cone biopsy excisor (FCBE) could be optimized in family medicine by restricting the use of the FCBE to the treatment of CIN II or III among women over the age of 30, allowing it to be used by practitioners with appropriate training, and performing the procedure with the backup support of our gynecology colleagues.1

Fischer Cone Biopsy Technique

The FCBE procedure uses preset sizes of electrodes that allow a hinge to be formed within the cervical os. The selection of FCBE sizes is based on the use of Lugol iodine application to the cervix and guided by sites of previous cervical disease that have been discovered during cervical biopsy. The Mulhem et al1 case series reported excellent results. FCBE is a device that can provide greater control over the area excised. However, to become an accepted alternative, the FCBE may need to be evaluated in an adequately powered case-control study comparing the standard of care and excisional biopsy, including LEEP, with the FCBE. Rigorous translational science in clinical implementation to support claims of superior outcomes will provide the data needed to entice new adopters of this new technology. The Mulhem article provides evidence that this technology works, but further evidence is needed to support the use of FCBE in clinical practice. In the case series presented, the placement of the electrode within the cervical os demonstrated reduced injuries to surrounding tissues, lower bleeding, and less pain, thus supporting continued clinical trials and use of this technology. Further, the completeness of diseased tissue excision was excellent, suggesting that further study is warranted. It is conceivable that future clinical trials may identify specific indications for FCBE, such as single-quadrant cervical disease, which would be better addressed with an FCBE instead of the LEEP.15

Reimbursement

Because the use of the FCBE involves identification of the cervical os and placement of an electrode inside the cervical os, there may be scope to consider reimbursement cost setting at a higher rate based on the higher degree of skill that is needed to perform the technique compared with the use of cervical excisional biopsies including LEEP, where no electrodes are placed inside the cervical os.

Conclusion

Overall, the FCBE is a promising technology with the potential for inclusion within family practices and for use by family physicians with experience conducting the cervical excisional biopsy, including the LEEP procedure. We have the opportunity to generate implementation data in clinical practice to support evidence-based inclusion of this new technology as an option in the management of abnormal Papanicolaou smears.

Notes

  • Funding: none.

  • Conflict of interest: none declared.

  • See Related Article on Page 154.

References

  1. ↵
    Mulhem E, Kennedy EL, Lick D. Treatment of cervical dysplasia with the Fischer cone biopsy excisor in a family medicine office: a case series. J Am Board Fam Med 2010; 23: 154–8.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Grumbach K. Redesign of the health care delivery system: a Bauhaus “form follows function” approach. JAMA 2009; 302: 2363–4.
    OpenUrlCrossRefPubMed
  3. Starfield B. Family medicine should shape reform, not vice versa. Fam Pract Manag 2009; 16: 6–7.
    OpenUrlPubMed
  4. Evans TE, Palmer E, Abercrombie S, et al. Advocacy: the time is now. Ann Fam Med 2009; 7: 376–7.
    OpenUrlFREE Full Text
  5. Rosenthal TC. The medical home: growing evidence to support a new approach to primary care. J Am Board Fam Med 2008; 21: 427–40.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Khanna N, Nesbitt L, Roghmann MC, Tacket C. Translation of clinical research into practice: defining the clinician scientist. Fam Med 2009; 41: 440–3.
    OpenUrlPubMed
  7. ↵
    American Cancer Society. What are the key statistics about cervical cancer? Available at http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_cervical_cancer_8.asp?sitearea=. Accessed 27 December 2009.
  8. ↵
    Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004; 191: 105–13.
    OpenUrlCrossRefPubMed
  9. ↵
    Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45: 107–14. Epub 2007 Jun 2.
    OpenUrlCrossRefPubMed
  10. ↵
    Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007; 11: 201–22. Erratum in J Low Genit Tract Dis 2008;12:255.
    OpenUrlCrossRefPubMed
  11. ↵
    Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol 2007; 107: 554–62.
    OpenUrlCrossRefPubMed
  12. ↵
    Massad LS, Jeronimo J, Schiffman M, National Institutes of Health/American Society for Colposcopy and Cervical Pathology (NIH/ASCCP) Research Group. Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol 2008; 111: 1279–84.
    OpenUrlCrossRefPubMed
  13. ↵
    Wentzensen N, Schiffman M, Dunn ST, et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009; 124: 964–9.
    OpenUrlCrossRefPubMed
  14. ↵
    Solomon D, Stoler M, Jeronimo J, Khan M, Castle P, Schiffman M. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities. Obstet Gynecol 2007; 110(2 Pt 1): 288–95.
    OpenUrlCrossRefPubMed
  15. ↵
    Apple Medical Corporation. Fischer cone biopsy excisor. Available at http://www.applemed.com/product.php?product=fischer_cone_biopsy_excisor. Accessed 27 December 2009.
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family Medicine: 23 (2)
The Journal of the American Board of Family Medicine
Vol. 23, Issue 2
March-April 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treating Cervical Dysplasia: Why Does It Matter?
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Treating Cervical Dysplasia: Why Does It Matter?
Niharika Khanna
The Journal of the American Board of Family Medicine Mar 2010, 23 (2) 151-153; DOI: 10.3122/jabfm.2010.02.100005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treating Cervical Dysplasia: Why Does It Matter?
Niharika Khanna
The Journal of the American Board of Family Medicine Mar 2010, 23 (2) 151-153; DOI: 10.3122/jabfm.2010.02.100005
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • The Big Picture
    • HPV Vaccine
    • Management of CIN
    • Family Medicine's Role in the Management of CIN
    • Fischer Cone Biopsy Technique
    • Reimbursement
    • Conclusion
    • Notes
    • References
  • References
  • Info & Metrics
  • PDF

Related Articles

  • Treatment of Cervical Dysplasia with the Fischer Cone Biopsy Excisor in a Family Medicine Office: A Case Series
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Empowering Family Physicians in Medical Staff Leadership to Foster Physician Well-Being
  • Maternity Care Deserts: Key Drivers of the National Maternal Health Crisis
  • Training in Gender Affirming Care is Medically Necessary
Show more Commentaries

Similar Articles

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire